Therapy Watch expands oncology and IBD portfolios
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US.
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US. CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both first-line and later-line patients, resulting in over 2000 patient record forms (PRFs).
A safe place to talk about Crohn’s
Published in eyeforpharma April 2017 by Mariel Metcalfe
Anxiety and embarrassment are a vicious circle for people with Crohn’s disease. The psychological and emotional effects of this complex and often unrecognised condition not only dominate patients’ lives but raise the risk of further outbreaks.
Understanding and empathy around Crohn’s are in short supply. It is a relatively low-profile disease, with periods of remission broken by highly disruptive flare-ups. The very nature of those flare-ups tends to ensure that Crohn’s stays below the radar.
Reviewing “real-world” patient cases to better understand disease remission in CD and the management of relapses
Following a poster presentation at the gastroenterology conference, UEG Week, Laurent Chanroux shares results from a study based on real-world patient cases to better understand disease remission in Crohn’s disease (CD) and the management of relapses.
Crohn's disease (CD) is a chronic inflammatory bowel disorder with a relapsing and remitting course and no known cure. The introduction of biologic therapy a decade ago has offered a new option for patients failing conventional therapy. However, clinical data suggests that although biologic agents have improved the outlook for many patients with moderate to severe CD, patients may still not be attaining remission. To help physicians manage their patients and achieve short and long-term goals with these new agents, it is important to review how these therapies may be optimised to ensure the best results.